Imugene is pleased to announce that its CD19 oncolytic...

Imugene is pleased to announce that its CD19 oncolytic virotherapy drug candidate onCARlytics (on-CAR-19, CF33-CD19 HOV4), has dosed the first patient in the intravenous monotherapy arm of the Phase 1 clinical trial.
Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours.
The trial aims to evaluate the safety and efficacy of two routes of administration, intratumoural (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.
The combination arm of the study will include onCARlytics combined with CD19 targeting bispecific monoclonal antibody blinatumomab (marketed as Blincyto® by Amgen).
onCARlytics has the potential to target and eradicate solid tumours that otherwise cannot be treated with Blincyto® therapy alone.
OASIS is a dose escalation trial being conducted in the United States, with the first IVpatient dosed at City of Hope in California. Additional sites are expected to open for recruitment across the US with 52 patients proposed to take part in the trial.

This is one small step forward and the big news of the first patient dosed in combination with Blincyto by Amgen will be forthcoming and will be a game changer in the treatment of solid tumours. Can you imagine the anticipation at Amgen head office right now not to mention their competitors. Very good Imugene.